Impact of interleukin-1β antibody (canakinumab) on glycaemic indicators in patients with type 2 diabetes mellitus: Results of secondary endpoints from a randomized, placebo-controlled trial

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy

Steven E. Kahn, Steven M. Haffner, Mark Heise et al. · New England Journal of Medicine · 2006 · 2.9K citations

Medicine, Endocrinology, Pharmacotherapy +13

Use of Canakinumab in the Cryopyrin-Associated Periodic Syndrome

Helen J. Lachmann, Isabelle Koné‐Paut, Jasmin Kuemmerle‐Deschner et al. · New England Journal of Medicine · 2009 · 858 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +11

Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)

Paul M. Ridker, Tom Thurén, Andrew Zalewski et al. · American Heart Journal · 2011 · 793 citations · Full text

Medicine, Immunology, Pharmacology +14

Two Randomized Trials of Canakinumab in Systemic Juvenile Idiopathic Arthritis

Nicolino Ruperto, Hermine I. Brunner, Pierre Quartier et al. · New England Journal of Medicine · 2012 · 709 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +14

Cytotoxicity of Human <i>p</i> I 7 Interleukin-1 for Pancreatic Islets of Langerhans

Klaus Bendtzen, Thomas Mandrup‐Poulsen, Jørn Nerup et al. · Science · 1986 · 531 citations

Life Sciences, Endocrinology, Immunology +14